CBIO - NASDAQ
Crescent Biopharma, Inc.
$17.95
+5.6%Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
At a Glance
Live SnapshotCrescent Biopharma, Inc. Management Team
Mr. Christian B. Dinneen-Long
General Counsel & Company Secretary
Mr. Chinmaya Rath
Senior Vice President & Chief Business Officer
Mr. Bruce Johnson
Senior Vice President & Chief Commercial Officer
Mr. Shantha Tyavanagimatt Ph.D.
Senior Vice President of Technical Operations
Ms. Stephanie R. Irish CPA
Vice President of Accounting
Crescent Biopharma, Inc. Insider Positioning
During the last 12 months, insiders have purchased $20.80M worth of CBIO shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
1.4M
18.24M
0
0.00
+18.2M
+$18.24M
9-12 Months
187.6K
2.56M
0
0.00
+2.6M
+$2.56M
Top Buyers
Fairmount Funds Management Llc
Director, 10 Percent Owner:
$18.38M
Pinkas Jan
Officer: Chief Scientific Officer
$1.87M
Violin Jonathan
Director
$138K
Balcom Alexandra
Director
$138K
Lubner David Charles
Director
$138K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $20.80M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
CBIO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 21, 2026 | June 02, 2026 | 2026 | |
DEF 14A DEF 14A 2024 N/A | April 01, 2024 | May 01, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 21, 2023 | May 19, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 11, 2022 | May 18, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 05, 2021 | May 05, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 16, 2020 | May 22, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 10, 2019 | May 17, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 13, 2018 | May 18, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 20, 2017 | May 25, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | April 11, 2016 | May 17, 2016 | 2016 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.